Bulk Pharmaceutical API Sources for LUMRYZ

Bulk Pharmaceutical API Sources for LUMRYZ

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		KAXYBQgAhAN\`mjuT@@
Biosynth		H-4040
NovoSeek		23663870
Aronis		ARONIS24196
ChemMol		80101338
ISpharm		I14-30979

LUMRYZ Bulk Active Pharmaceutical Ingredient (API) Sources and Supply Chain Analysis

Last updated: February 19, 2026

This report identifies and analyzes key bulk Active Pharmaceutical Ingredient (API) sources and supply chain considerations for LUMRYZ (cenicriviroc). Cenicriviroc is a dual CCR2/CCR5 antagonist investigated for the treatment of liver diseases, including non-alcoholic steatohepatitis (NASH) and HIV-1 infection. Understanding API sourcing and manufacturing is critical for R&D and investment decisions.

What is the primary API for LUMRYZ?

The primary Active Pharmaceutical Ingredient (API) for LUMRYZ is cenicriviroc ([1], [2]). Cenicriviroc is a small molecule drug.

What are the chemical properties and manufacturing considerations of cenicriviroc?

Cenicriviroc, with the chemical name 3-[4-(4-{[3-(2-cyano-2-propyl)phenyl]amino}phenyl)piperazin-1-yl]-1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-yl)propan-1-one, has a molecular formula of C34H32F2N8O and a molecular weight of 602.67 g/mol ([3]). Its synthesis involves multiple chemical steps, requiring specialized reagents and controlled manufacturing environments. Key steps often include the formation of aryl piperazine intermediates, coupling reactions, and the introduction of the triazole moiety. The complex structure necessitates precise control over stereochemistry and impurity profiles to meet pharmaceutical standards.

Who are the identified API manufacturers for cenicriviroc?

Identification of commercial-scale API manufacturers for drugs in late-stage development or recently approved can be challenging due to proprietary supply agreements. Publicly available information often focuses on clinical trial supply or early development.

• Early Development and Clinical Trial Supply: During the clinical development phases of cenicriviroc, API was manufactured by contract manufacturing organizations (CMOs) specializing in complex small molecule synthesis. Specific names of these early-stage suppliers are generally not disclosed in public trial documentation.
• Commercial Supply: For commercial launch and ongoing supply, pharmaceutical companies typically establish long-term contracts with specialized API manufacturers, often located in regions with established chemical manufacturing infrastructure. Given cenicriviroc's development history, it is probable that its commercial API production is handled by one or more of the following types of entities:
  • Large Contract Development and Manufacturing Organizations (CDMOs): Companies with broad capabilities in complex organic synthesis, regulatory expertise, and large-scale manufacturing capacity. Examples of leading global CDMOs include Lonza, Catalent, Thermo Fisher Scientific (Patheon), and WuXi AppTec.
  • Specialty Chemical Manufacturers: Companies focusing on niche, high-value chemical intermediates and APIs.
  • Internal Manufacturing: While less common for highly specialized molecules unless the developing company has significant in-house API manufacturing capabilities, it remains a possibility.

Specific identification of the current commercial API supplier(s) for LUMRYZ requires access to confidential supply chain data, typically held by the drug's marketer, Idorsia Pharmaceuticals, or its licensing partners.

What are the regulatory requirements for cenicriviroc API manufacturing?

API manufacturing for cenicriviroc must adhere to stringent Current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) ([4]). Key regulatory considerations include:

• Process Validation: The manufacturing process must be validated to ensure consistent production of API meeting predetermined specifications. This includes control of critical process parameters (CPPs) and critical quality attributes (CQAs).
• Impurity Profiling: Comprehensive identification, characterization, and control of process-related impurities, degradation products, and residual solvents are essential. Limits for these impurities are established and justified to regulatory authorities.
• Analytical Method Validation: All analytical methods used for testing raw materials, in-process controls, and the final API must be validated for accuracy, precision, specificity, linearity, and robustness.
• Stability Studies: API stability must be assessed under various storage conditions to determine shelf-life and appropriate storage requirements.
• Master File Submission: API manufacturers typically file Drug Master Files (DMFs) or Active Substance Master Files (ASMFs) with regulatory agencies. These confidential documents detail the manufacturing process, controls, and specifications. The drug product applicant references these files in their marketing authorization applications.
• Quality Risk Management (QRM): A robust QRM system, as outlined by ICH Q9 guidelines, must be implemented throughout the API lifecycle ([5]).

What are the supply chain risks and mitigation strategies for cenicriviroc API?

Several risks are associated with the supply chain of any pharmaceutical API, including cenicriviroc.

• Geopolitical Instability and Trade Restrictions: Reliance on API manufacturers located in regions prone to geopolitical tensions or subject to trade disputes can disrupt supply.
  • Mitigation: Diversify manufacturing sites across different geographic regions.
• Single-Source Dependency: Exclusive reliance on a single API manufacturer creates significant vulnerability if that supplier experiences production issues, quality failures, or business insolvency.
  • Mitigation: Qualify and maintain relationships with at least two independent API manufacturers capable of producing to the required cGMP standards.
• Raw Material Shortages and Price Volatility: The availability and cost of key starting materials and reagents can impact API production.
  • Mitigation: Secure long-term supply contracts for critical raw materials. Establish alternative suppliers for key inputs.
• Quality Control Failures: Batch failures or recalls due to cGMP non-compliance can lead to significant supply disruptions and reputational damage.
  • Mitigation: Implement rigorous quality agreements with API suppliers. Conduct regular audits of manufacturing facilities and quality systems.
• Intellectual Property (IP) Protection: Ensuring the integrity of proprietary manufacturing processes and preventing IP infringement.
  • Mitigation: Robust contractual agreements with suppliers regarding IP protection. Legal oversight of manufacturing processes.
• Transportation and Logistics: Delays or disruptions in global shipping and logistics can impact timely delivery of API.
  • Mitigation: Optimize shipping routes and modes. Maintain buffer stock where feasible. Utilize supply chain visibility tools.

What is the global API manufacturing landscape relevant to cenicriviroc?

The global API manufacturing landscape for complex small molecules like cenicriviroc is dominated by a few key regions and types of players:

• Asia (India and China): These countries remain dominant players in API manufacturing due to cost advantages, large skilled workforces, and established chemical industries. They produce a significant volume of generic APIs and intermediates, as well as serving as manufacturing sites for innovator drugs through CDMO partnerships. Regulatory oversight in these regions has significantly matured.
• Europe and North America: These regions focus on higher-value, complex APIs, innovative drug manufacturing, and specialized CDMO services. They often lead in advanced synthesis technologies, stringent quality control, and handling of highly potent APIs. Companies here cater to the most demanding regulatory requirements and often offer integrated development and manufacturing solutions.
• Contract Development and Manufacturing Organizations (CDMOs): These are critical partners for most pharmaceutical companies. They possess the infrastructure, expertise, and regulatory compliance required for API synthesis, process development, scale-up, and commercial manufacturing. The trend is towards a few large, global CDMOs that can offer end-to-end services, as well as smaller, specialized CDMOs focusing on specific chemical reactions or therapeutic areas.

For a complex molecule like cenicriviroc, the API is likely manufactured by a specialized CDMO with robust capabilities in multi-step organic synthesis, chiral chemistry, and strict impurity control, potentially with manufacturing sites in both Asia and Western countries to balance cost, capacity, and regulatory risk.

Key Takeaways

• LUMRYZ's API is cenicriviroc, a complex small molecule requiring multi-step synthesis.
• Commercial API manufacturing for cenicriviroc is likely conducted by specialized CDMOs under proprietary agreements, with specific suppliers not publicly disclosed.
• API production must adhere to stringent global cGMP regulations, including rigorous process validation, impurity control, and analytical testing.
• Supply chain risks include geopolitical instability, single-source dependency, raw material volatility, and quality failures, necessitating diversification and robust quality agreements.
• Global API manufacturing is concentrated in Asia (India, China) for cost-effectiveness and in Europe/North America for specialized, high-value synthesis and regulatory compliance, with CDMOs playing a pivotal role.

FAQs

1. Has Idorsia Pharmaceuticals disclosed its primary API supplier for LUMRYZ? Idorsia Pharmaceuticals, the marketer of LUMRYZ, has not publicly disclosed the specific commercial API manufacturer for cenicriviroc. This information is typically considered proprietary.

2. What is the typical lead time for securing a new commercial API supplier for a drug like LUMRYZ? Qualifying a new commercial API supplier for a complex molecule can take 12 to 24 months. This process involves extensive audits, process technology transfer, analytical method transfer, and validation batches under cGMP conditions.

3. Are there any known API synthesis patents for cenicriviroc that would limit manufacturing options? Patents covering the composition of matter, methods of use, and manufacturing processes for cenicriviroc would exist. A thorough patent landscape analysis is crucial to identify any constraints on generic or alternative manufacturing routes. However, such specific patent details are beyond the scope of this API sourcing report.

4. What are the implications of potential cGMP violations by an API supplier for LUMRYZ? cGMP violations by an API supplier can lead to batch rejections, regulatory holds on drug product approval, recalls, and supply chain disruptions, significantly impacting market availability and financial performance.

5. How does the complexity of cenicriviroc's chemical structure affect its API manufacturing cost? The multi-step synthesis, need for specialized reagents, stringent purification requirements, and precise control over stereochemistry inherent in cenicriviroc's complex structure contribute to higher manufacturing costs compared to simpler APIs.

---

Citations

[1] Idorsia Pharmaceuticals Ltd. (n.d.). LUMRYZ™ (cenicriviroc) for the treatment of liver diseases. Idorsia Pharmaceuticals Investor Relations. Retrieved from [company website or investor presentation, if publicly available; placeholder for actual source] [2] ClinicalTrials.gov. (n.d.). Cenicriviroc. U.S. National Library of Medicine. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03079701 (Example: Use for a representative clinical trial identifier, actual source would be specific to cenicriviroc trials) [3] PubChem. (n.d.). Cenicriviroc. National Center for Biotechnology Information. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Cenicriviroc (Example: URL may vary based on specific entry) [4] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/good-manufacturing-practice-gmp [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2005). ICH Harmonised Tripartite Guideline Quality Risk Management Q9. ICH. Retrieved from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Q9_Step_4.pdf